The Bull Rankings scorecard — our quality-growth score is 75.7 / 100, built from three pillars scored 0–100: Quality 59, Growth 90, Value 83 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free cash flow shrinking about 1% next year, then recovering toward 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Addus HomeCare’s growth engine is firing on all cylinders. Revenue grew 15.9% year-over-year in the quarter ended 2026-06-30, outpacing most healthcare services names, while free cash flow hit $155 million over the trailing twelve months. The company’s return on equity sits at 9.2%, a level that our model scores at 59/100 for Quality — not elite, but solid for a services business with modest leverage (debt-to-equity of 0.09). The real kicker is the Growth pillar, where our model awards a 90/100, the highest of the three. That’s not just a label; it’s a reflection of consistent top-line expansion in an industry where aging demographics and payer preference for home-based care are structural tailwinds. The stock’s 20.1 P/E may look full, but the PEG of 1.06 suggests the multiple is justified if the growth persists. The market isn’t pricing in continuation, though; the reverse DCF says it expects cash flow to stall.
What the business actually is
Addus sells time and expertise, not widgets. Its Personal Care segment handles the basics: bathing, grooming, medication reminders, meal prep, and housekeeping for elderly, chronically ill, or disabled patients who want to stay in their homes. The Hospice segment provides palliative nursing, social work, and spiritual counseling for those with terminal diagnoses. Home Health rounds out the trio with skilled nursing and therapy services. The Personal Care segment is the revenue engine — non-medical, high-frequency care that insurers and families increasingly favor over institutional settings. That’s the durable wedge: a service that’s both necessary and scalable, delivered where the patient lives.
Why it can (or can't) keep compounding
The moat isn’t a patent or a drug; it’s sticky relationships and payer contracts. Medicare Advantage plans and state Medicaid programs funnel patients to providers like Addus because home care beats hospital readmissions. The company’s 7.1% profit margin, while modest, has held up because the model relies on recurring visits, not one-time procedures. Our model’s Quality score of 59 reflects middling returns, not a weak balance sheet. Still, the 9.2% ROE shows capital is being put to work efficiently, even if the business isn’t compounding capital at tech-like rates. The real durability test is execution: keeping caregivers staffed, managing state-by-state licensing, and fending off regional competitors. So far, the growth suggests it’s winning.
The valuation question
The stock trades at 20.1 times trailing earnings, which isn’t cheap, but the PEG of 1.06 implies the multiple is fair if the company sustains its 15.9% revenue growth. Our model’s reverse DCF, however, tells a different story: today’s price embeds roughly -1% annual free-cash-flow growth (in year one, recovering toward 3% a year by year ten). That’s pessimistic on the surface, but it’s a direct read of what the market is paying for. The implied growth is far below the 15.9% revenue expansion posted in the quarter ended 2026-06-30, which means the price assumes a sharp slowdown rather than optimism. The question isn’t whether Addus can keep growing — it’s whether the market is overestimating how quickly that growth decays.
The bear case
The weakest pillar in our model is Quality, scored at 59/100, and the bear case centers on execution risk. A 7.1% profit margin isn’t generous, and if labor costs rise or reimbursement rates get squeezed, that margin could compress fast. The company’s leverage is low, but the business isn’t asset-heavy — the real risk is operational. The recent leadership shake-up, with the COO departure and interim replacement, adds noise to the execution story. If caregiver retention sags or state licensing delays pile up, the growth engine stalls. The market is already pricing in a slowdown; a margin crisis would be worse.
What would change our mind
If the Personal Care segment’s growth slips below 10% year-over-year for two consecutive quarters, the Growth pillar weakens. If the profit margin dips below 6%, the Quality score erodes further. Either would force a reassessment of the PEG and the reverse DCF’s implied growth. Until then, the thesis holds.